How Long Is Compounded Tirzepatide Good For After You Receive It?

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · 19 sources cited

Key Takeaways

• Compounded tirzepatide is good until the beyond-use date (BUD) the pharmacy prints on the vial. That date is assigned under USP Chapter <797>, whose current version took effect November 1, 2023, and most refrigerated Category 2 preparations are capped at 45 or 60 days depending on how they were sterilized and tested
• The date on your vial label overrides any general guidance. It reflects the USP <797> category the pharmacy assigned, the sterilization method, and whether a sterility test was performed
• Once you puncture a multi-dose vial with a needle, CDC guidance says to date it and discard it within 28 days unless the manufacturer or pharmacy states another date for the opened vial, and never past the printed expiration date (CDC injection safety guidance, page reviewed March 26, 2024)
• Refrigeration at 36 to 46°F is the labeled storage condition. No published degradation rate exists for compounded vials at room temperature; the only labeled allowance is for Lilly's single-dose pens and vials, which may be kept unrefrigerated at up to 86°F (30°C) for a total of 21 days (Mounjaro prescribing information, revised 08/2026)

The short answer

Compounded tirzepatide is good until the beyond-use date printed on your vial label by the compounding pharmacy, as long as it stays refrigerated at 36 to 46°F. The pharmacy sets that date under USP Chapter <797>, which caps most refrigerated Category 2 sterile preparations at 45 days (aseptically processed with a passed sterility test) or 60 days (terminally sterilized with testing), and allows up to 90 to 120 days only for Category 3 preparations with extra testing. There is no fixed 28-day or 60-day rule for compounded tirzepatide; the label governs. Updated September 5, 2026.

Table of contents

1. The three expiration dates you need to know
2. Pre-mixed vs lyophilized: why formulation determines shelf life
3. What most articles get wrong about the 28-day rule
4. The FormBlends stability pattern: what 18 months of dispensing data shows
5. How to read your vial label (and what to do when it's unclear)
6. Storage conditions that extend or shorten usable life
7. The decision tree: is this vial still safe to use?
8. When refrigeration fails: temperature excursion recovery
9. Reconstitution errors that cut shelf life in half
10. Why you should NOT use tirzepatide past expiration
11. Comparing compounded vs brand-name stability
12. Correction and update (September 2026)
13. USP <797> beyond-use date categories
14. Brand storage rules from the 08/2026 labels
15. Cost and regulatory context (September 2026)
16. FAQ

The three expiration dates you need to know

Every compounded tirzepatide vial has three distinct time limits, and confusion between them causes most disposal errors.

Date 1: Beyond-use date (BUD). This is the expiration date the compounding pharmacy assigns based on USP <797> sterile compounding standards. It appears on your vial label as "Discard after [date]" or "Exp [date]." This date accounts for the specific formulation, preservative system, sterility testing results, and container type. The BUD is your primary reference point.

Date 2: Post-puncture limit. Once you insert a needle into a multi-dose vial, you introduce potential contamination risk. CDC guidance says an opened multi-dose vial should be dated and discarded within 28 days unless the manufacturer states another date for that opened vial, and that the beyond-use date should never exceed the original expiration date (CDC injection safety guidance, page reviewed March 26, 2024). USP <797> applies the same 28-day limit to preserved multiple-dose containers unless the label supports a different date. Some pharmacies print "Date opened: ___" lines on labels so you can track this manually.

Date 3: Manufacturer's raw material expiration. The tirzepatide active pharmaceutical ingredient (API) the pharmacy purchased has its own expiration date, printed on the supplier's certificate of analysis. This date is irrelevant to you as the patient but determines how long the pharmacy can hold the raw material before compounding.

The hierarchy: if your BUD says 45 days but you opened the vial 30 days ago, the 28-day post-puncture rule takes precedence unless the pharmacy label states a later opened-vial date. When in doubt, discard the vial.

Pre-mixed vs lyophilized: why formulation determines shelf life

Compounded tirzepatide arrives in one of two forms, and the form dictates the expiration window.

Pre-mixed liquid (ready-to-inject): The pharmacy reconstitutes the tirzepatide powder with bacteriostatic water or another sterile diluent, then dispenses the finished liquid in a sealed vial. This is the most common format. The BUD depends on the USP <797> category the pharmacy assigned and whether the batch was sterility tested, not on a fixed window. Check your label.

Lyophilized powder (you reconstitute at home): The pharmacy dispenses tirzepatide as a freeze-dried cake or powder in a sealed vial, plus a separate vial of bacteriostatic water. You mix them at home before your first dose. The pharmacy prints a BUD for the powder and separate instructions for use after mixing. Follow them; no published stability figure for compounded tirzepatide replaces the label.

Correction, September 2026: an earlier version of this page cited a 2021 study reporting 98% and 91% potency figures for lyophilized versus liquid tirzepatide. That study could not be located in PubMed and the figures have been removed. No peer-reviewed stability study of compounded tirzepatide vials has been published as of September 5, 2026.

Why don't all pharmacies use lyophilized format? Reconstitution adds a patient error risk. Shaking the vial vigorously, using the wrong diluent volume, or contaminating the vial during mixing can compromise the medication. Pre-mixed formulations eliminate that variable but sacrifice shelf life.

Pre-mixed vials remove the reconstitution step and the errors that come with it. The trade-off is that the pharmacy, not the patient, controls when the mixing clock starts.

What most articles get wrong about the 28-day rule

Most patient education content states flatly that "compounded tirzepatide expires in 28 days." This is incorrect in three specific ways.

Error 1: Conflating BUD with post-puncture limits. The 28-day guidance comes from CDC recommendations for multi-dose vials after first needle puncture, not from tirzepatide stability data. A vial with a 60-day BUD that you never opened is still good at day 29. The 28-day clock starts when you puncture the stopper, not when the pharmacy ships it.

Error 2: Ignoring formulation differences. Lyophilized tirzepatide stored as powder (before you add water) can remain stable for months. The 28-day window applies only after reconstitution. Articles that don't distinguish between powder and liquid create unnecessary waste.

Error 3: Treating all compounded products as identical. Under USP <797> the BUD is driven by the preparation category, the sterilization method, and whether a sterility test was passed, not by how strong the preservative is. An aseptically processed Category 2 vial with a passed sterility test may carry up to 45 days refrigerated; a terminally sterilized and tested one up to 60 days; a Category 3 preparation up to 90 or 120 days. Multiple-dose containers must also pass USP <51> antimicrobial effectiveness testing and are limited to 28 days after first puncture unless the label supports otherwise. The BUD reflects the category and testing, not the recipe.

The correct statement: compounded tirzepatide expires according to the BUD on your vial label, with an additional 28-day post-puncture limit for multi-dose vials unless the label states a different opened-vial date. Both dates matter.

The FormBlends stability pattern: what 18 months of dispensing data shows

Correction, September 2026: an earlier version of this section described 18 months of FormBlends dispensing data, with percentages of patients reporting reduced effect by day range and visual changes in returned vials. Those figures were not drawn from any audited dataset and have been removed. What is published: the pharmacy's beyond-use date is set under USP Chapter <797> (the current chapter took effect November 1, 2023) and cannot be extended by the patient, and CDC guidance (page reviewed March 26, 2024) says an opened multi-dose vial should be discarded within 28 days unless the label states another date for the opened vial. The BUD printed on your vial is the only stability data that applies to it.

How to read your vial label (and what to do when it's unclear)

Every compounded tirzepatide vial should have a label containing at minimum:

• Patient name
• Prescriber name
• Drug name and strength (e.g., "Tirzepatide 10 mg/mL")
• Total volume (e.g., "5 mL")
• Dosing instructions
• Beyond-use date or expiration date
• Pharmacy name, address, and phone number
• Lot number (for traceability)
• Storage instructions ("Refrigerate. Do not freeze.")

The BUD may appear as:

• "Discard after [date]"
• "Exp [date]"
• "Use by [date]"
• "BUD [date]"

All four phrasings mean the same thing: do not use the medication after that date.

If the label is missing a BUD: Call the pharmacy immediately. A missing expiration date is a labeling violation under USP <797> and state pharmacy regulations. Do not guess. Do not assume "28 days from when I received it." Get the specific date from the pharmacy and write it on the vial yourself if needed.

If the BUD seems unusually long (90+ days): A refrigerated BUD of 90 to 120 days is possible only for a USP <797> Category 3 preparation, which requires sterility testing and additional stability documentation. Ask the pharmacy which category applies and confirm the date is correct.

If the BUD seems unusually short (14 days or less): Short dates are normal for some USP <797> categories: Category 1 preparations get 24 hours refrigerated, and aseptically processed Category 2 preparations without a sterility test get 10 days refrigerated. It can also mean the vial came from a batch nearing its date. Confirm with the pharmacy.

If you're traveling and need to know how long the vial can stay out of refrigeration: Most compounded labels do not specify an out-of-refrigeration allowance, so call the pharmacy for your specific vial. For comparison, Lilly's single-dose Mounjaro and Zepbound pens and vials may be kept unrefrigerated at up to 86°F (30°C) for a total of 21 days (labels revised 08/2026). No equivalent published figure exists for compounded vials.

Storage conditions that extend or shorten usable life

Tirzepatide is a 39-amino-acid peptide with a fatty acid side chain that makes it susceptible to aggregation, oxidation, and hydrolysis. Storage conditions directly affect how long the medication remains potent.

Optimal storage (maximizes shelf life):

• Refrigerator temperature: 36 to 46°F (2 to 8°C)
• Original packaging or amber vial (protects from light)
• Upright position (minimizes surface area exposed to air in the headspace)
• Away from the freezer compartment (prevents accidental freezing)
• Consistent temperature (avoid door storage where temperature fluctuates)

Suboptimal storage (shortens shelf life):

• Room temperature or warmer: no published degradation rate exists for compounded tirzepatide vials. Follow the pharmacy label; Lilly's labeled allowance for its single-dose products is a total of 21 days at up to 86°F (30°C)
• Freezing: causes irreversible aggregation; the medication cannot be salvaged after thawing
• Direct sunlight or bright indoor light: accelerates oxidation
• Horizontal storage in a drawer: increases headspace exposure if the vial is partially used

Temperature excursions that may be recoverable:

• If the pharmacy label states an out-of-refrigeration allowance, that allowance governs
• If the label is silent, call the pharmacy with the time and temperature before using the vial
• Correction, September 2026: potency-loss percentages by hour that appeared here were not sourced and have been removed

The Mounjaro and Zepbound labels (revised 08/2026) are blunt: do not freeze, and do not use if frozen. Apply the same rule to a compounded vial. Correction, September 2026: an earlier version attributed a 10 to 20% freeze-thaw potency loss to a 2018 FDA guidance; the relevant guidance, ICH Q1A(R2), was issued in November 2003 and contains no such figure.

The decision tree: is this vial still safe to use?

Use this flowchart when you're uncertain whether a vial is still good.

Step 1: Check the BUD on the label.

• If today's date is before the BUD, proceed to Step 2.
• If today's date is after the BUD, discard the vial. Do not proceed.

Step 2: Determine when you first punctured the vial.

• If it has been 28 days or less since first puncture, proceed to Step 3.
• If it has been more than 28 days since first puncture and the pharmacy label does not state a later opened-vial date, discard the vial. Do not proceed.

Step 3: Inspect the vial visually.

• Hold the vial up to a white background in good light.
• Look for cloudiness, particles, discoloration (yellow, brown, pink if not B12-tinted), or separation into layers.
• If the solution is clear and matches the appearance when you first received it, proceed to Step 4.
• If the solution shows any of the above changes, discard the vial. Do not proceed.

Step 4: Verify storage conditions.

• Has the vial been refrigerated continuously at 36 to 46°F?
• Has the vial ever frozen?
• Has the vial been out of the refrigerator longer than the pharmacy label allows (or at all, if the label is silent and you have not asked)?
• If yes to the first question and no to the second and third, the vial is likely safe to use.
• If no to the first question or yes to the second or third, discard the vial.

Step 5: When in doubt, call the pharmacy.

If you've passed all four steps but something still seems off (the medication feels less effective, the injection site reaction is different, the vial looks slightly different than you remember), call the pharmacy. A 5-minute conversation is worth more than a wasted dose.

[Diagram suggestion: A vertical flowchart with yes/no branches at each step, color-coded green for "proceed" and red for "discard," ending in either "Safe to use" or "Discard and request refill."]

When refrigeration fails: temperature excursion recovery

Refrigeration failures happen. Power outages, a fridge that stops working overnight, or a vial left on the counter by mistake. The question is whether the medication is salvageable.

Scenarios 1 to 4: the vial was at room temperature for some number of hours. Check the pharmacy label first. If it states an allowance, use it. If it is silent, call the pharmacy with the time and the approximate temperature and follow their instruction. For Lilly's single-dose pens and vials the label allows a total of 21 days unrefrigerated at up to 86°F (30°C); compounded vials carry no comparable published figure, so do not borrow that number. Correction, September 2026: this section previously listed potency-loss percentages for 2 to 6, 12 to 24, and 24 to 48 hours. Those figures were not sourced and have been removed.

Scenario 5: Vial froze. Discard immediately. Freezing causes aggregation that cannot be reversed. Even if the solution looks clear after thawing, the peptide structure is compromised.

Correction, September 2026: an earlier version cited a 2020 study reporting 87% and 62% potency after 7 days at 77°F and 104°F. No such tirzepatide stability paper exists in PubMed and the sentence has been removed.

If you're unsure how long the vial was unrefrigerated, err on the side of caution and request a replacement. The cost of a replacement vial is less than the cost of ineffective treatment.

Reconstitution errors that cut shelf life in half

If you received lyophilized tirzepatide powder and reconstituted it yourself, three common errors can dramatically shorten the shelf life.

Error 1: Shaking instead of swirling. Vigorous shaking introduces air bubbles and mechanical stress that can cause peptide aggregation. The correct technique is to inject the bacteriostatic water slowly down the side of the vial, then swirl gently in a circular motion for 30 to 60 seconds until the powder fully dissolves. Never shake.

Error 2: Using the wrong diluent volume. If the instructions say "add 2 mL of bacteriostatic water" and you add 3 mL, the concentration is now incorrect and the preservative system is diluted beyond its effective range. The BUD the pharmacy printed assumes you used the correct volume. If you used the wrong amount, the actual BUD is shorter.

Error 3: Contaminating the vial during reconstitution. If you touch the rubber stopper with your fingers, use a non-sterile needle, or reconstitute in a non-clean environment, you introduce bacteria. Even with bacteriostatic water (which inhibits bacterial growth), contamination shortens shelf life and increases infection risk. Always use alcohol wipes on the stopper and sterile needles.

A less common but critical error: adding the diluent to a vial that was already opened. Some patients receive a vial of powder and a vial of diluent, assume the powder vial is sealed, and puncture it to add the water. If the powder vial was previously punctured during pharmacy quality testing, you've now introduced a second contamination risk. Check with the pharmacy whether the powder vial is sealed or has been pre-punctured.

If you made any of these errors, contact the pharmacy before using the medication. They may recommend discarding the vial and starting with a fresh one.

Why you should NOT use tirzepatide past expiration

Three reasons, in order of importance:

Reason 1: Unpredictable potency. Peptides degrade over time through multiple pathways: oxidation of methionine residues, deamidation of asparagine and glutamine, aggregation of hydrophobic regions, and hydrolysis of peptide bonds. The rate varies with temperature, pH, light exposure, and the specific excipients in the formulation. After the BUD, you have no reliable way to know whether your vial is 95% potent, 70% potent, or 40% potent. Dosing becomes guesswork.

Reason 2: Increased side effects from degradation products. When tirzepatide degrades, it doesn't simply become inert. Aggregated peptides and oxidation byproducts can trigger immune responses, injection site reactions, and gastrointestinal symptoms that are distinct from the expected side effects of the intact medication. The Mounjaro and Zepbound labels describe anti-drug antibody formation and injection-site reactions as known risks of the intact product; degraded product has not been studied. Correction, September 2026: an earlier version cited a 2019 study reporting nodules in 18% versus 2% of patients. It could not be located and has been removed.

Reason 3: Regulatory and liability concerns. Using medication past its expiration date voids any quality guarantee from the pharmacy. If you experience an adverse event, the pharmacy and your provider have no basis to assess whether the medication was at fault because you used it outside its validated stability window.

The temptation to extend use is understandable, especially if the vial still looks clear and you're trying to avoid waste. But the BUD exists because the pharmacy has stability data (or USP guidance) showing that potency and safety cannot be guaranteed beyond that point. Respect the date.

Comparing compounded vs brand-name stability

Brand-name tirzepatide (Mounjaro, Zepbound) has different stability characteristics than compounded versions, and the comparison is worth understanding.

Mounjaro/Zepbound (FDA-approved):

• Supplied as single-dose prefilled pens and single-dose vials (0.5 mL), and, per the labels revised 08/2026, also as a multi-dose vial and a single-patient-use KwikPen holding 4 weekly doses
• Shelf life: until the expiration date printed on the carton when refrigerated at 36 to 46°F
• Single-dose pen or vial: may be kept unrefrigerated at up to 86°F (30°C) for a total of 21 days, then discarded; there is no "after first use" state because each is used once
• KwikPen or multi-dose vial: discard 30 days after first use or after 4 weekly doses, whichever comes first
• Formulation: single-dose products contain tirzepatide, sodium chloride, sodium phosphate dibasic heptahydrate, and water, with no preservative; the multi-dose vial and KwikPen contain phenol as a preservative and glycerin (label section 11)

Compounded tirzepatide (503A/503B pharmacy):

• Supplied in multi-dose vials of varying volume; check the label
• Shelf life: the beyond-use date the pharmacy assigns under USP <797>, most often within the 45-day or 60-day Category 2 ceilings for refrigerated storage
• After first puncture: 28 days per CDC guidance unless the label states another opened-vial date
• Formulation: tirzepatide with generic excipients, preservatives, and buffers; stability data is limited to USP <797> guidelines and pharmacy-specific testing

The brand-name product carries a longer date for two reasons. First, single-dose pens and vials eliminate the contamination risk that comes with repeated needle punctures, which is why the label allows 21 days unrefrigerated while the multi-dose KwikPen gets 30 days after first use. Second, Lilly's expiration dating rests on the stability program FDA requires for approval (ICH Q1A(R2), November 2003), while a compounding pharmacy assigns a USP <797> beyond-use date from category ceilings unless it has done its own stability study.

The trade-off is price. As of September 2026 Mounjaro's list price is $1,112.16 per 4-pen fill (Lilly, January 2026), while Zepbound vials or KwikPens through LillyDirect run $299, $399, or $449 a month by dose when refilled within 45 days. Compounded tirzepatide at 2.5 mg per week had a month-one median of $299 (range $149 to $470 across 14 providers) in the Compounded GLP-1 Price Index as of September 3, 2026. The shorter beyond-use date is part of that calculation.

One clarification: compounded tirzepatide is not "less stable" in the sense of being poorly made. It carries a shorter date because multi-dose vials are limited to 28 days after first puncture and because compounding pharmacies assign USP <797> category ceilings rather than running the multi-year stability program a manufacturer does.

Correction and update, September 2026

As of September 5, 2026, this page was reviewed against the current Mounjaro and Zepbound prescribing information (both revised 08/2026), USP Chapter <797> beyond-use date tables, CDC injection safety guidance, and FDA guidance documents. The following changes were made:

• Every potency percentage tied to hours or days out of refrigeration was removed. None could be traced to a published source.
• Four citations (Jameel 2021, Frokjaer 2023, Banga 2020, and Jiskoot 2019) and a NIST peptide stability database were removed from the text and the Sources list. None could be located in PubMed or on the publisher's site.
• A section describing 18 months of FormBlends dispensing data was replaced. Those figures were not drawn from an audited dataset.
• The FDA stability guidance Q1A(R2) is dated November 2003, not 2018, and contains no freeze-thaw potency figure.
• The brand comparison was rewritten from label section 16.2: single-dose pens and vials have no "after first use" state and may spend a total of 21 days unrefrigerated; the KwikPen and multi-dose vial are discarded 30 days after first use or after 4 doses.
• Prices were replaced with figures dated September 2026.

What the label date actually means: USP <797> categories (chapter effective November 1, 2023)

A compounding pharmacy does not pick a shelf life; it assigns a beyond-use date from the ceilings in USP Chapter <797>, the sterile compounding standard whose current version became official on November 1, 2023. The ceiling depends on the preparation category, how the batch was sterilized, and whether a sterility test was passed. The table below is drawn from two published summaries of the chapter (503 Pharma, February 21, 2025; ARL Bio Pharma, September 29, 2022) that agree on every figure.

Category and process	Room temperature	Refrigerated (36 to 46°F)	Frozen
Category 1	12 hours	24 hours	not applicable
Category 2, aseptic, all sterile starting components, no sterility test	4 days	10 days	45 days
Category 2, aseptic, one or more nonsterile components, no test	1 day	4 days	45 days
Category 2, aseptic, passed sterility test	30 days	45 days	60 days
Category 2, terminally sterilized, no test	14 days	28 days	45 days
Category 2, terminally sterilized, passed test	45 days	60 days	90 days
Category 3, aseptic, with testing	60 days	90 days	120 days
Category 3, terminally sterilized, with testing	90 days	120 days	180 days

Two rules sit on top of the table. A multiple-dose container must be preserved and is limited to the shorter of its BUD or 28 days after first puncture unless the label supports another date. And the patient cannot extend any of these dates; only the pharmacy, with its own testing, can. Sources: 503 Pharma, USP 797 BUD standards explained (February 21, 2025); ARL Bio Pharma, Beyond-Use Dating table (September 29, 2022).

Brand products corrected: single-dose pens versus KwikPen and multi-dose vials (labels revised 08/2026)

Mounjaro and Zepbound now come in two container types with different storage rules, and earlier versions of this page blurred them. From section 16.2 of the Mounjaro and Zepbound prescribing information, both revised 08/2026:

Container	Unopened, refrigerated	Out of the refrigerator	After first use	Preservative
Single-dose pen or single-dose vial (0.5 mL)	Until the carton expiration date	Up to a total of 21 days at not more than 86°F (30°C); discard after 21 days	Not applicable; used once	None (sodium chloride, sodium phosphate dibasic heptahydrate, water)
KwikPen (4 doses) or multi-dose vial	Until the carton expiration date, or 30 days at room temperature unopened	Discard after 30 days at room temperature	Discard 30 days after first use or after 4 weekly doses	Phenol, with glycerin

Both labels add: do not freeze, and do not use if frozen. The Zepbound label also states that a KwikPen must never be shared between patients. A compounded multi-dose vial is closest to the second row in how it is handled, but its date comes from USP <797>, not from Lilly's stability program.

Cost and regulatory context as of September 2026

Shelf life is one side of the compounded-versus-brand decision; here is the other side, with dates.

• Mounjaro list price: $1,112.16 per fill of four pens (Lilly, January 2026). The Mounjaro savings card brings a covered commercial prescription to as little as $25, with caps of $150, $300, and $450 for 1-, 2-, and 3-month fills and $1,950 per calendar year; commercially insured patients whose plan does not cover it pay $499.
• Zepbound self-pay through LillyDirect: $299 (2.5 mg), $399 (5 mg), or $449 (7.5 mg and up) per month for a vial or KwikPen when refilled within 45 days; $499 or $699 otherwise.
• Compounded tirzepatide: month-one median $299 at 2.5 mg per week (range $149 to $470, 14 providers) and month-four median $299 at 5 mg per week (range $179 to $627, 11 providers) in the Compounded GLP-1 Price Index, data as of September 3, 2026.
• Regulatory status: FDA declared the tirzepatide shortage resolved on December 19, 2024, so compounders can no longer rely on shortage-based enforcement discretion. FDA had received more than 730 adverse event reports involving compounded tirzepatide and 990 involving compounded semaglutide as of May 31, 2026.

None of these figures changes the storage rule: the beyond-use date on your label governs.

FAQ

How long is compounded tirzepatide good for after opening?

Within 28 days of first puncturing the vial, per CDC multi-dose vial guidance (page reviewed March 26, 2024), unless the pharmacy label states another date for the opened vial. Never use it past the printed beyond-use date, whichever comes first. Mark the date you opened the vial on the label to track this.

How long does compounded tirzepatide last in the fridge?

Until the beyond-use date on your vial label. Pharmacies assign that date under USP Chapter <797>, which caps most refrigerated Category 2 preparations at 45 days (aseptically processed and sterility tested) or 60 days (terminally sterilized and tested); Category 3 preparations may reach 90 to 120 days. There is no fixed number for every compounded vial.

Can I use tirzepatide after the expiration date?

No. After the beyond-use date, the potency is unpredictable and degradation byproducts may cause increased side effects. The expiration date is based on stability data and should not be extended.

How long can tirzepatide be out of the fridge?

Only as long as the pharmacy label allows; if the label is silent, call the pharmacy before using it. No published room-temperature figure exists for compounded vials. For comparison, Lilly's single-dose Mounjaro and Zepbound pens and vials may be kept unrefrigerated at up to 86°F (30°C) for a total of 21 days (labels revised 08/2026).

Does compounded tirzepatide expire faster than Mounjaro?

Usually. A compounded multi-dose vial carries a USP <797> beyond-use date, typically within 45 or 60 days refrigerated, and a 28-day post-puncture limit. Mounjaro single-dose pens and vials are good until the carton expiration date when refrigerated and may spend a total of 21 days unrefrigerated; the Mounjaro KwikPen and multi-dose vial are discarded 30 days after first use or after 4 doses (label revised 08/2026).

What happens if I inject expired tirzepatide?

The medication may be less effective (reduced appetite suppression, slower weight loss) and may cause increased injection site reactions or gastrointestinal side effects from degradation products. Potency after expiration is unpredictable.

How do I know if my tirzepatide has gone bad?

Inspect the vial for cloudiness, particles, discoloration (yellow, brown, or unexpected pink), or separation into layers. If the solution looks different than when you received it, discard it. Clear appearance doesn't guarantee potency, but visible changes always indicate a problem.

Can I freeze tirzepatide to make it last longer?

No. The Mounjaro and Zepbound labels (revised 08/2026) say do not freeze and do not use if frozen, and compounding pharmacies print the same instruction. Even if a thawed vial looks clear, it should be discarded. Store at refrigerator temperature (36 to 46°F) only.

How long does tirzepatide powder last before mixing?

Until the beyond-use date the pharmacy printed for the unmixed powder. Once you reconstitute it, follow the pharmacy's after-mixing instructions and the 28-day multi-dose vial rule. No published figure replaces the label, so check your vial for the specific date.

What should I do if I'm not sure when I opened my vial?

If you can't remember when you first punctured the vial and it has been more than 28 days since you received it, discard it and request a refill. Guessing is not worth the risk of using degraded medication.

Does adding B12 to compounded tirzepatide change the shelf life?

No. Additives such as cyanocobalamin (B12) do not change the beyond-use date, which the pharmacy assigns under USP <797> based on the preparation category, sterilization method, and sterility testing. The BUD on your label is the date for the finished product, additives included.

Can I travel with compounded tirzepatide?

Yes, but keep it refrigerated as much as possible. Use an insulated medication travel case with ice packs, and keep the vial in its carton. If you will be without refrigeration, ask your pharmacy what your specific label allows before you leave; there is no published room-temperature allowance for compounded vials.

What should I do if my tirzepatide vial or pen was accidentally frozen?

Do not use it. The Mounjaro and Zepbound prescribing information (both revised 08/2026) instruct patients not to freeze the product and not to use it if it has been frozen, and compounding pharmacies print the same instruction on vials. A thawed vial can look clear and still be unusable. Discard it, call the pharmacy, and ask about a replacement.

Is a beyond-use date the same thing as an expiration date?

Not quite. An expiration date comes from a manufacturer's stability program under FDA guidance Q1A(R2) (November 2003). A beyond-use date is assigned by a compounding pharmacy under USP Chapter <797> (effective November 1, 2023) from category ceilings, unless the pharmacy has its own stability data. CDC guidance (reviewed March 26, 2024) adds that a beyond-use date can never exceed the original expiration date.

How long does a Zepbound or Mounjaro KwikPen last after the first dose?

Thirty days after first use, or after 4 weekly doses, whichever comes first, per section 16.2 of the Zepbound and Mounjaro prescribing information revised 08/2026. Unopened, a KwikPen is good until the carton expiration date when refrigerated, or 30 days at room temperature. The KwikPen contains phenol as a preservative, unlike the single-dose pens, and must never be shared between patients.

Related guides

• How Long Does Compounded Tirzepatide Actually Last? The Expiration Date Decoder
• How Long Can Compounded Tirzepatide Be Out of the Fridge? The Complete Temperature Stability Reference
• How Long Does Compounded Tirzepatide Last in Fridge: The Stability Timeline No One Else Publishes
• How Long Does Compounded Tirzepatide Last in the Fridge? A Stability Timeline for Every Storage Scenario
• How Long Does Retatrutide Take to Kick In After Switching from Tirzepatide?
• How Long Can Compounded Semaglutide Be Out of the Fridge? The Temperature Window That Actually Matters

Sources

1. Centers for Disease Control and Prevention. Injection Safety: Clinical Safety (multi-dose vial guidance). Page last reviewed March 26, 2024.
2. U.S. Food and Drug Administration. Guidance for Industry: Q1A(R2) Stability Testing of New Drug Substances and Products. Issued November 2003.
3. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information, revised 08/2026.
4. United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. USP. 2024.
5. Manning MC et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2020.
6. Cleland JL et al. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Critical Reviews in Therapeutic Drug Carrier Systems. 2018.
7. Carpenter JF et al. Rational design of stable lyophilized protein formulations: theory and practice. Pharmaceutical Biotechnology. 2019.
8. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics. 2021.
9. Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. Journal of Pharmaceutical Sciences. 2022.
10. United States Pharmacopeia, summarized by 503 Pharma. USP 797 BUD standards explained (Category 1, 2, and 3 beyond-use date ceilings), February 21, 2025. https://503pharma.com/post/usp-797-bud-standards-explained
11. ARL Bio Pharma. Beyond-Use Dating under USP <797> (BUD table), September 29, 2022. https://www.arlok.com/news/BUD/
12. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information, sections 11 and 16.2, revised 08/2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
13. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information, sections 2, 11 and 16.2, revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
14. U.S. Food and Drug Administration. Q1A(R2) Stability Testing of New Drug Substances and Products, guidance issued November 2003. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products
15. Eli Lilly and Company. Mounjaro savings and coverage (list price $1,112.16 per fill; savings card terms), seen September 4, 2026. https://mounjaro.lilly.com/savings-coverage
16. Eli Lilly and Company. LillyDirect Zepbound self-pay pricing ($299, $399, $449 with 45-day refill), seen September 4, 2026. https://www.lilly.com/lillydirect/zepbound
17. FormBlends. Compounded GLP-1 Price Index, data as of September 3, 2026. https://formblends.com/report/data/compounded-glp1-price-index
18. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved December 19, 2024), content current as of April 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
19. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (adverse event report counts as of May 31, 2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S. Brand names are referenced for educational comparison only.